Hope for high risk chronic lymphocytic leukemia after ibrutinib failure

Chronic lymphocytic leukemia (CLL) is characterized by progressive accumulation of mature appearing, dysfunctional CD5 positive B lymphocytes. The prognosis of the disease is extremely variable and ranges from patients free of symptoms, having almost normal life span, to an aggressive course of disease which is unresponsive to therapy and often leads to short survival.